AbCellera Biologics
Vancouver-based AbCellera Biologics researches and develops human antibodies using proprietary technology.
Vancouver-based AbCellera Biologics researches and develops human antibodies using proprietary technology.
AbCellera positions its edge in creating antibody medicines from difficult targets. Its microfluidics-based single-cell screening engine, developed from University of British Columbia research, is presented as capable of generating medical countermeasures within 60 days under the DARPA Pandemic Prevention Platform project. That claim was exercised through the Lilly collaboration that produced bamlanivimab, the first COVID-19 antibody to enter human study, followed by bebtelovimab.
Commercial validation is framed as scale: more than 40 partners and more than 100 antibody programs since 2015, plus discovery partnerships with Moderna on mRNA-encoded antibodies, Vertex on multispecific T-cell engagers with 28 million dollars upfront, and Jazz Pharmaceuticals on T-cell engaging multispecifics for solid tumors with 56 million dollars upfront for two programs plus milestones and royalties. The company channels the same GPCR, ion-channel, bispecific, and conjugate capabilities into its wholly owned pipeline.
Source: abcellera.com
As of September 2026 AbCellera is a clinical-stage company whose near-term value rests on ABCL635, an NK3R antibody for menopausal vasomotor symptoms that reported positive top-line Phase 2 data on August 10, 2026. Days later the company priced an oversubscribed 200 million dollar public offering of shares and pre-funded warrants at 9 dollars 75 cents to fund pipeline research and clinical advancement. Second-quarter 2026 results showed 4.1 million dollars of revenue, a 55.4 million dollar net loss, and over 565 million dollars of cash and marketable securities.
Partnered revenue optionality comes from the July 2026 Vertex T-cell engager collaboration and the June 2026 Jazz gastrointestinal-cancer multispecific collaboration, alongside the earlier Moderna mRNA-antibody agreement. Key risks reflected in the record are clinical concentration in ABCL635 and ABCL575, reliance on partnership milestones, and the history of COVID-19 antibody authorizations being revoked as variants evolved.
Source: investors.abcellera.com
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. Its platform integrates biology, computation, and engineering to move programs from target to the clinic, with stated strength in complex transmembrane proteins such as GPCRs and ion channels, bispecifics, and antibody-drug conjugates. Since 2015 the company reports working with more than 40 partners on more than 100 antibody drug programs.
Alongside partnered work with companies including Pfizer, Moderna, Vertex Pharmaceuticals, and Jazz Pharmaceuticals, AbCellera advances an internal pipeline led by ABCL635 for menopausal vasomotor symptoms, ABCL575 for atopic dermatitis, plus ABCL688 and ABCL386. The company is listed on Nasdaq under ticker ABCL and reported over 565 million dollars in cash and marketable securities at the end of the second quarter of 2026.
Source: abcellera.com
AbCellera's offering has two parts: a partnered antibody discovery platform built on single-cell screening for difficult targets including GPCRs, ion channels, bispecifics, and antibody-drug conjugates; and an internal pipeline of ABCL635, an NK3R antibody for menopausal vasomotor symptoms in Phase 1/2, ABCL575, an OX40L-blocking antibody for atopic dermatitis in Phase 1, ABCL688, an autoimmunity antibody in IND-enabling studies, and ABCL386, an oncology candidate.
The company cites more than 20 additional discovery programs across indications and modalities. ABCL635 reported positive top-line Phase 2 data in August 2026, meeting primary efficacy endpoints for frequency and severity of moderate-to-severe vasomotor symptoms with a favorable tolerability profile.
Source: abcellera.com